GlaxoSmithKline (NYSE:GSK) Price Target Increased to GBX 1,900 by Analysts at JPMorgan Chase & Co.

GlaxoSmithKline (NYSE:GSKGet Rating) had its price objective upped by JPMorgan Chase & Co. from GBX 1,740 ($22.18) to GBX 1,900 ($24.22) in a research note issued to investors on Thursday morning, The Fly reports.

Several other analysts have also recently weighed in on GSK. DZ Bank cut shares of GlaxoSmithKline from a buy rating to a hold rating in a research report on Friday, February 11th. StockNews.com upgraded shares of GlaxoSmithKline from a buy rating to a strong-buy rating in a research report on Wednesday, March 30th. Stifel Nicolaus started coverage on shares of GlaxoSmithKline in a research report on Monday, February 28th. They issued a hold rating on the stock. Zacks Investment Research cut shares of GlaxoSmithKline from a buy rating to a hold rating and set a $46.00 target price on the stock. in a research report on Tuesday, January 4th. Finally, Barclays lifted their target price on shares of GlaxoSmithKline from GBX 1,675 ($21.35) to GBX 1,775 ($22.62) in a research report on Thursday, April 14th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Hold and a consensus target price of $1,240.33.

NYSE GSK opened at $45.58 on Thursday. GlaxoSmithKline has a 1 year low of $37.31 and a 1 year high of $46.97. The company has a debt-to-equity ratio of 0.96, a current ratio of 0.79 and a quick ratio of 0.54. The stock has a market capitalization of $115.86 billion, a PE ratio of 19.06, a P/E/G ratio of 1.87 and a beta of 0.72. The company’s 50 day simple moving average is $43.55 and its two-hundred day simple moving average is $43.18.

GlaxoSmithKline (NYSE:GSKGet Rating) last posted its earnings results on Wednesday, February 9th. The pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.06. The business had revenue of $12.84 billion for the quarter, compared to analysts’ expectations of $12.62 billion. GlaxoSmithKline had a net margin of 12.90% and a return on equity of 26.33%. During the same period in the prior year, the company posted $0.62 EPS. On average, research analysts anticipate that GlaxoSmithKline will post 3.23 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Thursday, April 7th. Shareholders of record on Friday, February 25th were issued a $0.615 dividend. This represents a $2.46 dividend on an annualized basis and a yield of 5.40%. The ex-dividend date was Thursday, February 24th. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.52. GlaxoSmithKline’s dividend payout ratio (DPR) is 99.17%.

Several institutional investors and hedge funds have recently made changes to their positions in GSK. Manchester Capital Management LLC boosted its stake in shares of GlaxoSmithKline by 70.9% during the 3rd quarter. Manchester Capital Management LLC now owns 651 shares of the pharmaceutical company’s stock valued at $25,000 after purchasing an additional 270 shares in the last quarter. Tyler Stone Wealth Management bought a new stake in shares of GlaxoSmithKline during the 4th quarter valued at about $26,000. Clearview Wealth Advisors LLC bought a new stake in shares of GlaxoSmithKline during the 4th quarter valued at about $27,000. Allegheny Financial Group LTD bought a new stake in shares of GlaxoSmithKline during the 4th quarter valued at about $27,000. Finally, Tsfg LLC boosted its stake in shares of GlaxoSmithKline by 67.9% during the 1st quarter. Tsfg LLC now owns 618 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 250 shares in the last quarter. 26.59% of the stock is currently owned by hedge funds and other institutional investors.

About GlaxoSmithKline (Get Rating)

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Recommended Stories

The Fly logo

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.